Impax cuts nearly 50 employees to save money

Impax Laboratories ($IPXL), which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money. The cut of a total of 49 positions at the company is expected to save $8 million a year. From here on out, Impax's branded R&D efforts will focus on products in Phase II and above, the company said in a statement today. Ongoing FDA concerns about Impax' manufacturing has delayed approval of Rytary for some time. Story | More

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.